Linkedin
RLS logo_header
Linkedin

Oncology programs CUE-101 and CUE-102 deprioritized to enhance focus on autoimmune program CUE-401

“While we plan to focus our resources on our novel autoimmune programs, we intend to preserve the potential value of our clinical oncology programs by retaining requisite clinical capabilities to enable maturation of clinical survival data in the current ongoing Phase 1 trials of CUE-101 and CUE-102. As such, we are actively pursuing third party support through partnerships and collaborations to further develop these programs. We believe the strategic measures we are taking will strengthen operational efficiencies and extend our capital runway,” said Daniel Passeri, chief executive officer of Cue Biopharma.

Read the full story on "Oncology programs CUE-101 and CUE-102 deprioritized to enhance focus on autoimmune program CUE-401"

Share:

More News

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Gen T-cell Engaging Multispecific Antibodies

“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies

Final Patient Dosed in Ph 2 DURIPANC Study in Metastatic Pancreatic Cancer

AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most

FAILED TRIAL: Ph 3 TRIDENT trial of TTFields did not meet primary endpoint of significant OS increase in GBM patients when used early

“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT

FDA Fast Track Designation for Givastomig in 1L HER2-Neg Metastatic Gastric Cancer

“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a